4 active not recruiting, 3 recruiting, 2 terminated, 1 completed. 6 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 2, Recruiting 2, Terminated 1, Withdrawn 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Cutaneous Squamous Cell Carcinoma of the Head and Neck: new trials by email Literature Review of Cutaneous Squamous Cell Carcinoma of the Head and Neck trials Research Report on Cutaneous Squamous Cell Carcinoma of the Head and Neck
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence High-Frequency Ultrasound, Dermoscopy - Basal Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC) | Not yet recruiting | Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji | 400 | 2025-12-23 | 2026-01-23 | |
| Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation Audiometric Test, Interview - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Not applicable | Recruiting | Emory University | 118 | 2025-08-25 | 2026-07-16 |
| Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck Sentinel lymph node biopsy (SLNB), Lymphadenectomy, Adjuvant Definitive Therapy - Cutaneous Squamous Cell Carcinoma of the Head and Neck, Clinically Node-Negative (cN0) | Phase 2 | Withdrawn | University of California, Davis | 2025-06-25 | 2026-08-31 | |
| Towards Cure Via Only Ultra-short ICB in CSCC Nivolumab, Ipilumimab - Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer | Phase 2 | Recruiting | The Netherlands Cancer Institute | 41 | 2025-05-14 | 2025-05-29 |
| Surveillance of Regional Nodal Basins in Patients With Primary High Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Ultrasound - Cutaneous Squamous Cell Carcinoma of the Head and Neck | Terminated | Johns Hopkins University | 1 | 2024-02-01 | 2026-03-09 | |
| Deep sequencIng in Cutaneous Squamous CEll caRciNomas Cemiplimab - Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 11 | 2023-05-26 | 2026-09-21 |
| Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma Pembrolizumab - Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Cancer | Phase 2 | Recruiting | Queensland Health | 27 | 2022-06-28 | 2022-08-01 |
| Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region Regular care with additionally administration of questionnaires - Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Completed | Maastricht University Medical Center | 78 | 2022-02-28 | 2026-01-06 | |
| Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study Cisplatin, Intensity-Modulated Proton Therapy, Quality-of-Life Assessment - Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary | Phase 2 | Active not recruiting | Mayo Clinic | 174 | 2022-02-16 | 2026-07-16 |
| Needs and Preferences of Patients With Head-neck Cutaneous SCC Regular care with additional administration of a semi-structured interview - Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Active not recruiting | Maastricht University Medical Center | 15 | 2021-11-01 | 2025-04-04 | |
| Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC Cemiplimab-Rwlc - Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 3 | 2020-06-25 | 2022-11-04 |
| Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment - Cutaneous Squamous Cell Carcinoma of the Head and Neck, Healthy Subject | Active not recruiting | M.D. Anderson Cancer Center | 100 | 2017-05-18 | 2026-05-20 |
Carcinoma, Squamous Cell (3) · Skin Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Head and Neck Neoplasms (2) · Hypopharyngeal Neoplasms (2) · Laryngeal Neoplasms (2) · Mouth Neoplasms (2) · Oropharyngeal Neoplasms (2) · Patient Satisfaction (2) · Carcinoma (1) · Carcinoma, Basal Cell (1) · Lymphatic Metastasis (1) · Margins of Excision (1) · Nasopharyngeal Carcinoma (1) · Neoplasms (1)
Neoplasms (7) · Neoplasms by Site (7) · Head and Neck Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Carcinoma (3) · Neoplasms, Squamous Cell (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Behavior (2) · Health Behavior (2) · Laryngeal Diseases (2) · Mouth Diseases (2) · Otorhinolaryngologic Diseases (2) · Otorhinolaryngologic Neoplasms (2)
Magnetic Resonance Spectroscopy (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Cisplatin (1) · Dermoscopy (1) · Hearing (1) · Immunotherapy (1) · Interviews as Topic (1) · Lymph Node Excision (1) · Neck Dissection (1) · Nivolumab (1) · Platinum (1) · Radiotherapy, Intensity-Modulated (1) · Sentinel Lymph Node Biopsy (1) · Specimen Handling (1) · Ultrasonography (1)
Maastricht University Medical Center (2) · Emory University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Johns Hopkins University (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji (1) · Peter MacCallum Cancer Centre, Australia (1) · Queensland Health (1) · The Netherlands Cancer Institute (1) · University of California, Davis (1)
United States (5) · Netherlands (3) · Australia (2) · Poland (1)
K Mosterd, MD, PhD (2) · Andrew Birkeland, MD (1) · Annette M Lim, MBBS, FRACP, PhD (1) · Christine H Chung, MD (1) · Clifton D Fuller (1) · Kristin Bibee, MD (1) · Lotje Zuur, Prof. Dr. (1) · Nicole C Schmitt, MD, FACS (1) · Rahul Ladwa, MD (1) · Scott C. Lester, M.D. (1)
K24DC022077 (1), P30CA093373 (1), P30CA138292 (1)